CyFlow CD135 Purified (RUO)
| 品番 | BH161449 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD135 PURI,BV10A4 | ||
| 包装単位 | 0.1 mg | ||
| 濃度 | 1 mg/ml | ||
| 推奨使用量 | - | ||
| 容量 | 0.1 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 Purified (BJ561896) Mouse IgG1 Purified (AS224818) |
||
| 反応性|交差吸着 | Human | レーザー | - |
| 抗原 | CD135, Flt3, Flk2, STK1 | 最大蛍光波長 | - |
| クローン | BV10A4 | 最大励起波長 | - |
| ホスト | Mouse | 標識/Format | Purified |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping | Phosphorylation |
| クローナリティ | monoclonal | アプリケーション | - |
Anti-Hu CD135 PURI,BV10A4
特異性
The mouse monoclonal antibody BV10A4 (BV10) reacts with CD135 antigen, a 130-160 kDa type III receptor tyrosine kinase that is involved in early steps of hematopoiesis
抗原情報
CD135 (FLT3, FLK2, STK-1) is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of FLT3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on various malignant hematopoietic cells.
利用方法
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Christensen JL, Weissman IL: Flk‑2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long‑term stem cells: a simple method to isolate long‑term stem cells. Proc·Natl·Acad·Sci·USA. 2001·Dec·4; 98(25):14541‑6. <·PMID:·11724967·>
• Haylock DN, Horsfall MJ, Dowse TL, Ramshaw HS, Niutta S, Protopsaltis S, Peng L, Burrell C, Rappold I, Buhring HJ, Simmons PJ: Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood. 1997·Sep·15; 90(6):2260‑72. <·PMID:·9310477·>
• Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica. 2005·Dec; 90(12):1617‑25. <·PMID:·16330434·>
• Rappold I, Ziegler BL, Köhler I, Marchetto S, Rosnet O, Birnbaum D, Simmons PJ, Zannettino AC, Hill B, Neu S, Knapp W, Alitalo R, Alitalo K, Ullrich A, Kanz L, Bühring HJ: Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood. 1997·Jul·1; 90(1):111‑25. <·PMID:·9207445·>
• Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Mosse C, Pardoll DM, Small D: Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc·Natl·Acad·Sci·USA. 2005·Nov·15; 102(46):16741‑6. <·PMID:·16272221·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>